Esophageal Cancer Clinical Trial
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
Summary
The purpose of this study is to see if adding two targeted drugs (bevacizumab and erlotinib) further improves the response to chemotherapy (5-FU, paclitaxel, carboplatin) and radiation therapy in patients with operable esophageal cancer.
Side effects (toxicity) information will also be collected.
Full Description
Surgical removal has been the standard treatment for operable esophageal cancer. However, recent studies have shown improved results when patients receive a short course of chemotherapy and radiation therapy prior to surgery.
Prior to surgery study treatment will be given over a 6 weeks (Days 1-42) period. Beginning Day 1 and continuing through Day 35 patients will receive a continuous infusion of 5-FU by vein. A small portable pump will be used to administer this drug into a tube that has been surgically inserted into the patient's vein. On Day 1 and 22 patients will also receive the drugs paclitaxel, carboplatin and bevacizumab by vein. Erlotinib is given by mouth beginning on Day 1 and continuing through Day 45. Patients will receive radiation therapy daily, Monday through Friday, beginning Day 1-35 (approximately 5 weeks).
Surgery will be performed approximately 12-14 weeks after beginning this combined treatment.
Eligibility Criteria
Inclusion Criteria:
Clinically confirmed esophageal or gastroesophageal junction cancer stage I, II or III
No prior treatment for esophageal cancer
Must be surgical candidate based on stage and location of disease
Measurable or evaluable disease
Able to be up and perform self care
Adequate liver, renal function and bone marrow function
Patients will have to have a central venous access device placed
Able to give written informed consent.
Age 18 or older
Exclusion Criteria:
Stage IV disease
Prior cancer treatment for advanced cancer in the last 5 years
Pregnant or lactating women
History of stroke, transient ischemic attacks, or acute MI within the past 6 months or any other serious cardiovascular disease
History of neurological disease
Recent history of blood in the sputum or vomitus
Non-healing wounds, ulcer or long bone fractures
History of bleeding problems or coagulation problems
History of abdominal fistula, gi perforation or intrabdominal abscess within 6 months
History of uncontrolled hypertension
Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have. You can then decide if you wish to participate.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 9 Locations for this study
Fort Myers Florida, 33901, United States
Jacksonville Florida, 32256, United States
Gainesville Georgia, 30501, United States
Louisville Kentucky, 40207, United States
Morristown New Jersey, 07960, United States
Canton Ohio, 44710, United States
Cincinnati Ohio, 45242, United States
Chattanooga Tennessee, 37404, United States
Nashville Tennessee, 37023, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.